May 04, 2022 / 08:30PM GMT
Operator
Good day, everyone, and welcome to Ligand Pharmaceuticals' First Quarter '22 Earnings Call. (Operator Instructions) Please note this call may be recorded.
It is now my pleasure to turn today's program over to Simon Latimer, Head of Investor Relations. Please go ahead.
Simon Latimer - Ligand Pharmaceuticals Incorporated - Head of IR
Thanks. Welcome to Ligand's first quarter of 2022 financial results and business update conference call. Our speakers for today's call are in separate locations. Speaking today for Ligand will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.
We'll use non-GAAP financial measures and some of our statements will be forward looking, including those relating to our financial condition, results of operations, financial guidance, the impact of the COVID-19 pandemic, and the expected timing completion effects of our previously announced plans to spin-off the OmniAb business to become a standalone public company pursuant to a business combination with the Avista Public Acquisition Corp. II.
Q1 2022 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers